Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound-guided Bilateral Superficial Cervical Plexus Block for Postoperative Pain in Neck Surgeries
NCT07539935Phase 4
Key facts
- Status
- Active, not recruiting
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
- Sponsor
- Sohag University
- Modality
- Small Molecules
- Drugs
- bupivacaine
- Conditions
- postoperative pain
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in postoperative pain (2 arms), sponsored by Sohag University. Primary endpoint: Analgesic effect of bilateral superficial cervical plexus block at 24 hours. Started Mar 2026; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Group will take the block
Superficial cervical plexus block guided by ultrasound with bupivacaine
Controlled group
Sham block with normal saline and Paracetamol (500 mg) tablets
03
Who it enrols
Patients aged 18-60 undergoing elective neck surgery under general anesthesia, excluding those with significant neurological or psychological disease, allergy to local anesthesia, uncorrected coagulopathy, severe neck deformity, infection at injection site, severe respiratory disease, or regular use of analgesics.
04
Endpoints
Primary
Analgesic effect of bilateral superficial cervical plexus block
Secondary
Total opioid consumption
Beyond the preview
Go deeper on NCT07539935.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539935.